Eli Lilly and Company is developing its tirzepatide in heart failure and sleep apnea, in addition to obesity, in an effort to overcome payer resistance to covering drugs for weight loss, Lilly diabetes president Mike Mason explained during the company’s recent earnings presentation.
He described Phase III studies in the two indications as not aimed at expanding the patient population, since obesity is already the broader indication, but rather at addressing reimbursement obstacles
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?